Genelux's (GNLX) "Buy" Rating Reiterated at HC Wainwright

Genelux (NASDAQ:GNLX - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $32.00 target price on the stock.

Separately, Benchmark reiterated a "speculative buy" rating and issued a $30.00 price objective on shares of Genelux in a research report on Wednesday, April 3rd.

Genelux Stock Performance

GNLX traded down $0.22 during mid-day trading on Monday, reaching $3.61. The stock had a trading volume of 73,269 shares, compared to its average volume of 123,912. The stock has a market capitalization of $97.47 million, a P/E ratio of -3.69 and a beta of -1.18. The firm's fifty day simple moving average is $4.90 and its two-hundred day simple moving average is $9.45. Genelux has a 52 week low of $3.06 and a 52 week high of $40.98.

Genelux (NASDAQ:GNLX - Get Free Report) last announced its quarterly earnings data on Friday, March 29th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.04). As a group, analysts expect that Genelux will post -0.81 EPS for the current fiscal year.

Insider Transactions at Genelux

In other Genelux news, major shareholder Aladar Szalay sold 33,061 shares of Genelux stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $3.30, for a total transaction of $109,101.30. Following the transaction, the insider now directly owns 1,195,731 shares in the company, valued at $3,945,912.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have sold 116,567 shares of company stock worth $402,686 in the last three months. Insiders own 11.70% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Woodward Diversified Capital LLC raised its stake in shares of Genelux by 2,326.2% in the 4th quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company's stock valued at $15,163,000 after purchasing an additional 1,037,663 shares during the period. Vanguard Group Inc. raised its stake in shares of Genelux by 1,660.1% in the 3rd quarter. Vanguard Group Inc. now owns 980,993 shares of the company's stock valued at $24,025,000 after purchasing an additional 925,258 shares during the period. AMG National Trust Bank acquired a new stake in shares of Genelux in the 3rd quarter valued at about $1,233,000. Bank of New York Mellon Corp raised its stake in shares of Genelux by 476.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 53,938 shares of the company's stock valued at $1,321,000 after purchasing an additional 44,584 shares during the period. Finally, Clarity Capital Partners LLC acquired a new stake in shares of Genelux in the 4th quarter valued at about $364,000. 37.33% of the stock is currently owned by institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.